Drug intelligence / Profile preview

NVP-2203-R2

Development stage: Phase 3
Lead developer: NVP Healthcare
Modality: Small Molecules
Administration: Oral

Overview

NVP-2203-R2 is a code name for an investigational drug that is part of the NVP-2203 series. It specifically targets tyrosine kinase enzymes that are overactive in certain cancer cells. By binding to the ATP-binding site of these enzymes, it inhibits their activity and prevents phosphorylation events required for cancer cell survival and proliferation[1]. The drug is being evaluated as an oral therapy in clinical trials, including phase 3 studies for efficacy and safety[2][5]. It may be administered alone or as part of a combination (e.g., with NVP-2203-R1)[5].

Targets

Tyrosine kinase

Beyond the preview

Go deeper on NVP-2203-R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-2203-R2.

Explore the full profile